143 related articles for article (PubMed ID: 19906049)
21. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
22. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
23. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy.
Motoki H; Koyama J; Izawa A; Tomita T; Miyashita Y; Takahashi M; Ikeda U
Echocardiography; 2014 Nov; 31(10):1230-8. PubMed ID: 24645985
[TBL] [Abstract][Full Text] [Related]
24. Effects of azelnidipine, a dihydropyridine calcium antagonist, on myocardial stunning in dogs.
Satoh K; Yamamoto A; Hoshi K; Ichihara K
Jpn J Pharmacol; 1998 Apr; 76(4):369-76. PubMed ID: 9623715
[TBL] [Abstract][Full Text] [Related]
25. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
[TBL] [Abstract][Full Text] [Related]
26. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.
Kuramoto K; Ichikawa S; Hirai A; Kanada S; Nakachi T; Ogihara T
Hypertens Res; 2003 Mar; 26(3):201-8. PubMed ID: 12675275
[TBL] [Abstract][Full Text] [Related]
27. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S; Kawamori R; Iwamoto Y; Saito I; Kuramoto K;
Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
[TBL] [Abstract][Full Text] [Related]
28. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.
Manabe S; Okura T; Fukuoka T; Higaki J
Eur J Pharmacol; 2007 Jul; 567(3):252-7. PubMed ID: 17544393
[TBL] [Abstract][Full Text] [Related]
29. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.
Takahashi K; Shimokado K; Yoshida M
Eur J Pharmacol; 2006 Dec; 552(1-3):162-9. PubMed ID: 17067573
[TBL] [Abstract][Full Text] [Related]
30. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
31. In vivo imaging of renal redox status during azelnidipine treatment.
Hirayama A; Ueda A; Oteki T; Nagase S; Aoyagi K; Koyama A
Hypertens Res; 2008 Aug; 31(8):1643-50. PubMed ID: 18971540
[TBL] [Abstract][Full Text] [Related]
32. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
Nakano K; Egashira K; Tada H; Kohjimoto Y; Hirouchi Y; Kitajima S; Endo Y; Li XH; Sunagawa K
J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension.
Tanaka T; Tsutamoto T; Sakai H; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2007 Aug; 30(8):691-7. PubMed ID: 17917316
[TBL] [Abstract][Full Text] [Related]
34. Cardiac effects of L/N-type Ca2+ channel blocker cilnidipine in anesthetized dogs.
Takahara A; Iwasaki H; Nakamura Y; Sugiyama A
Eur J Pharmacol; 2007 Jun; 565(1-3):166-70. PubMed ID: 17445796
[TBL] [Abstract][Full Text] [Related]
35. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
Ando K; Haneda M; Ito S; Kashihara N; Node K; Nangaku M; Shimosawa T; Kishimoto J; Fujita T
Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
[TBL] [Abstract][Full Text] [Related]
36. Effects of the new dihydropyridine derivative 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 6-(5-phenyl-3-pyrazolyloxy)hexyl ester on the cardiohemodynamics and the energy metabolism of ischemic myocardium.
Imai H; Matsui K; Ochi S; Nakazawa M; Nakagawa Y; Imai S
Arzneimittelforschung; 1987 Dec; 37(12):1348-52. PubMed ID: 3449062
[TBL] [Abstract][Full Text] [Related]
37. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
Suzuki H; Inoue T; Kobayashi K; Shoda J; Nakamoto H
Adv Perit Dial; 2006; 22():18-23. PubMed ID: 16983932
[TBL] [Abstract][Full Text] [Related]
38. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Li JM; Iwai M; Cui TX; Min LJ; Tsuda M; Iwanami J; Suzuki J; Mogi M; Horiuchi M
Mol Pharmacol; 2005 May; 67(5):1666-73. PubMed ID: 15695623
[TBL] [Abstract][Full Text] [Related]
39. Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.
Takano Y; Ueyama T; Ishikura F
J Cardiol; 2012 Jul; 60(1):18-22. PubMed ID: 22436293
[TBL] [Abstract][Full Text] [Related]
40. Comparison of effects of dihydropyridine calcium antagonists on left ventricular systolic and diastolic performance.
Cheng CP; Noda T; Nordlander M; Ohno M; Little WC
J Pharmacol Exp Ther; 1994 Mar; 268(3):1232-41. PubMed ID: 8138936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
